Top Medical Searches

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH (Reuters) – Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented.

 Read more…

Be Sociable, Share!
December 7th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us